GNTA

Genenta Science

GNTA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio-2.09

Market capitalization33.3M

Earnings per share-0.38

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-6.5M

Social

What share of all stock conversation is about GNTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jun 3

Genenta Science S.p.A. ($GNTA) is mentioned in relation to a potential breakthrough in treatment of RX drugs.
$GNTA is mentioned as a strong performer, with a 254% increase in value.
$GNTA is testing the $3 level, with some speculating about a bear attack.

Generated by AI

Sentiment

Of the messages about GNTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	61.14% -13.86
Bearish	—	—	—	38.86% +13.86

Bullish· Jun 2

Genenta Science S.p.A. ($GNTA) is transforming into Saentra Forge and acquiring Sòphia High Tech, an ESA space supplier, positioning it for a space pivot.
$GNTA has a clean share structure with a tiny ~13M float, contributing to its high-volume momentum breakout.
The company has closed the acquisition of remaining 80.5% of A.T.C., giving it 100% ownership of a profitable defense/tech firm, making it a strong buy alert.

Bearish· Jun 1

The company's recent deal to acquire A.T.C. may be a burden due to the 36-month lock-up on shares and the put option that allows sellers to force Genenta to buy back shares if the stock price falls below a certain threshold.
The option structure may limit Genenta's flexibility, as sellers can force the company to buy back shares if the stock price falls below a certain threshold, and the company can only repurchase shares if the price rises above a certain threshold.
The deal's terms, including the share-for-asset swap and the lack of governance protections for the A.T.C. sellers, may indicate a lack of confidence in the company's ability to manage its assets effectively.

Generated by AI

Topics

Of the messages about GNTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	63.65%
Analysts	—	—	—	10.52%
Controversies	—	—	—	1.07%
Earnings	—	—	—	0%
Macro	—	—	—	9.32%
Technical Analysis	—	—	—	15.45%

Mar 27

Genenta Science S.p.A. (GNTA) is evolving into Saentra Forge, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies.
Saentra Forge has signed a binding offer to acquire a controlling stake in Sòphia High Tech S.r.l., an Italian aerospace and defense manufacturer, with a commitment of EUR 6.0 million through two reserved capital increases.
The acquisition aims to reach a controlling stake upon the achievement of defined performance milestones, with Sòphia HT already profitable and expected to grow with connections to major space companies.

Generated by AI

Community

Of the messages about GNTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	6.36%
Newcomers	—	—	—	93.64%

Jun 1

The newcomer is focused on the potential for $GNTA to be a rare, hidden edge that most analysts and funds miss, due to its asymmetric technological moat.
The newcomer is excited about the potential for new technology to replace many drugs, and believes $GNTA is a key player in this space.
The newcomer is cautious about the high-risk transformation of $GNTA, as management is abandoning clinical-stage biotech to pursue a roll-up strategy in defense, space, and security.

Generated by AI

The Spring Assembly manufactured by Sòphia HT, a strategic Genenta investment, supports the separation of the launcher’s second and third stages Sòphia HT has been in serial production of the component since 2018 MILAN, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolving into Saentra Forge1, a strategic industrial consolidator focused on aerospace, defense, national security and biotechnology, today announced that Sòphia High Tech S.r.l. (Sòphia HT), the Italian ae

15d agosg.finance.yahoo.com

Genenta Science Provides Update on CEO Ownership

Genenta Science Provides Update on CEO Ownership...

1mo agoBarchart.com

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm ...

2mo agoBarchart.com

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

Sales rise 29.3% and EBITDA grows 68.1%; newly appointed Board of Directors to lead the next phase of aerospace and defense growthFiscal Year 2025 Highlights FY2025 sales rose 29.3% to €7.17 million; total value of production increased 34.7% to €8.47 millionEBITDA grew 68.1% to €1.61 million, expanding the EBITDA margin by approximately 380 basis points to 19.0%Operating profit advanced 80.8% to €1.21 million MILAN, July 22, 2026 (GLOBE NEWSWIRE) -- Genenta Science S.p.A. (Nasdaq: GNTA), evolvin

2mo agoYahoo! Finance Canada

12 Health Care Stocks Moving In Monday's Pre-Market Session - Advanced Biomed (NASDAQ:ADVB), Barinthus Bi

2mo agoBenzinga

Genenta Science Regains Full Effectiveness of Corporate Purpose Amendment After Milan Court Ruling

Detailed price information for Genenta Science S.P.A. ADR (GNTA-Q) from The Globe and Mail including charting and trades.

2mo agoThe Globe and Mail

Also Discussed

Investors talking about GNTA also mention

#	Name	Attention
1	AMC Robotics CorporationAMCI	0%0
2	Turbo Energy, S.A. American Depositary SharesTURB	0.01%new
3	Webuy Global Ltd.WBUY	0%-0.02
4	Quoin Pharmaceuticals, Ltd. American Depositary SharesQNRX	0%0
5	A SPAC III Acquisition Corp. Class A Ordinary SharesASPC	0%0
6	Abits Group IncABTS	0%new
7	CREV - Carbon Revolution Public Limited Ordinary Shares	——
8	GraniteShares 2x Long AMZN Daily ETFAMZZ	0%0
9	Mynd.ai, Inc. ADRMYND	0%0
10	Gaxos.ai Inc.GXAI	0%0

Genenta Science S.p.A. Sponsored ADR

Healthcare
Biotechnology

Genenta Science S.p.A. Sponsored ADR is a clinical-stage biotechnology company focused on developing gene and cell therapies for solid tumors. Its lead program, Temferon, is designed to deliver therapeutic activity directly within the tumor microenvironment using hematopoietic stem cell-based technology and immune-modulating mechanisms. The company’s platform is built around targeted biologic delivery through monocytes and macrophages, supporting research across difficult-to-treat cancers such as glioblastoma and other solid tumor indications. Genenta Science S.p.A. Sponsored ADR operates within the oncology and immunotherapy space, where it contributes to advanced precision medicine approaches aimed at improving the treatment of aggressive cancers. Based in Milan, Italy, the company is part of the broader life sciences sector and focuses on current clinical development programs and proprietary therapeutic platforms.

Website

Location

Via Olgettina No. 58

Milan, MI, 20132

Italy

Social

What share of all stock conversation is about GNTA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% +0

Jun 3

Genenta Science S.p.A. ($GNTA) is mentioned in relation to a potential breakthrough in treatment of RX drugs.
$GNTA is mentioned as a strong performer, with a 254% increase in value.
$GNTA is testing the $3 level, with some speculating about a bear attack.

Generated by AI

Sentiment

Of the messages about GNTA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	61.14% -13.86
Bearish	—	—	—	38.86% +13.86

Bullish· Jun 2

Genenta Science S.p.A. ($GNTA) is transforming into Saentra Forge and acquiring Sòphia High Tech, an ESA space supplier, positioning it for a space pivot.
$GNTA has a clean share structure with a tiny ~13M float, contributing to its high-volume momentum breakout.
The company has closed the acquisition of remaining 80.5% of A.T.C., giving it 100% ownership of a profitable defense/tech firm, making it a strong buy alert.

Bearish· Jun 1

The company's recent deal to acquire A.T.C. may be a burden due to the 36-month lock-up on shares and the put option that allows sellers to force Genenta to buy back shares if the stock price falls below a certain threshold.
The option structure may limit Genenta's flexibility, as sellers can force the company to buy back shares if the stock price falls below a certain threshold, and the company can only repurchase shares if the price rises above a certain threshold.
The deal's terms, including the share-for-asset swap and the lack of governance protections for the A.T.C. sellers, may indicate a lack of confidence in the company's ability to manage its assets effectively.

Generated by AI

Topics

Of the messages about GNTA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	—	—	63.65%
Analysts	—	—	—	10.52%
Controversies	—	—	—	1.07%
Earnings	—	—	—	0%
Macro	—	—	—	9.32%
Technical Analysis	—	—	—	15.45%

Mar 27

Genenta Science S.p.A. (GNTA) is evolving into Saentra Forge, a strategic industrial consolidator focused on biotech, defense, aerospace, and Italian national-security-related technologies.
Saentra Forge has signed a binding offer to acquire a controlling stake in Sòphia High Tech S.r.l., an Italian aerospace and defense manufacturer, with a commitment of EUR 6.0 million through two reserved capital increases.
The acquisition aims to reach a controlling stake upon the achievement of defined performance milestones, with Sòphia HT already profitable and expected to grow with connections to major space companies.

Generated by AI

Community

Of the messages about GNTA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	6.36%
Newcomers	—	—	—	93.64%

Jun 1

The newcomer is focused on the potential for $GNTA to be a rare, hidden edge that most analysts and funds miss, due to its asymmetric technological moat.
The newcomer is excited about the potential for new technology to replace many drugs, and believes $GNTA is a key player in this space.
The newcomer is cautious about the high-risk transformation of $GNTA, as management is abandoning clinical-stage biotech to pursue a roll-up strategy in defense, space, and security.

Generated by AI

Genenta Science

Social

Jun 3

Sentiment

Bullish· Jun 2

Bearish· Jun 1

Topics

Mar 27

Community

Jun 1

News

Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit

Genenta Science Provides Update on CEO Ownership

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

12 Health Care Stocks Moving In Monday's Pre-Market Session - Advanced Biomed (NASDAQ:ADVB), Barinthus Bi

Genenta Science Regains Full Effectiveness of Corporate Purpose Amendment After Milan Court Ruling

Also Discussed

Genenta Science S.p.A. Sponsored ADR

Company Information

Location

News

Sòphia High Tech Flight Hardware on Board VEGA-C VV30 as the European Launcher Carries Sentinel-3C and FLEX into Orbit

Genenta Science Provides Update on CEO Ownership

Genenta-backed Sòphia High Tech Brings Aerospace Precision Inside a Nuclear Fusion Reactor with ROMAN, a Robotic Arm

Genenta-Backed Sòphia High Tech Reports Fiscal Year 2025 Results

12 Health Care Stocks Moving In Monday's Pre-Market Session - Advanced Biomed (NASDAQ:ADVB), Barinthus Bi

Genenta Science Regains Full Effectiveness of Corporate Purpose Amendment After Milan Court Ruling

Also Discussed

Social

Jun 3

Sentiment

Bullish· Jun 2

Bearish· Jun 1

Topics

Mar 27

Community

Jun 1